Sleep, Energy & Cognition
Do Racetams and Other Nootropics Have Human Evidence?
The short answer
The evidence is older, thinner, and more mixed than the 'smart drug' marketing implies. A 2002 meta-analysis of 19 placebo-controlled trials found piracetam produced a favorable global impression of change in patients with dementia or cognitive impairment — but a 2023 network meta-analysis of frontotemporal dementia found piracetam significantly worsened neuropsychiatric symptoms (SMD 3.48), and a 2015 review concluded it doesn't appear effective for Lewy body dementia. In healthy volunteers specifically, a small 1990 trial found aniracetam, but not piracetam, reversed drug-induced memory impairment — one of the few controlled tests of a racetam in people without cognitive impairment. A 2022 pharmacology review of 'smart drugs' concluded their benefit in healthy people is uncertain and, when present, temporary. Most racetam trials were run in the 1980s-1990s, in small and often elderly clinical samples, not in the healthy adults now taking them for cognitive enhancement.
Quick answers
- What is it?
- Racetams (piracetam, aniracetam, oxiracetam) are a class of older "nootropic" compounds marketed as smart drugs, first developed in the 1960s for cognitive enhancement.
- Why are people interested in it?
- Racetams are sold today as cognitive enhancers for healthy people, so buyers want to know whether the trial evidence actually supports use outside dementia care.
- What has actually been studied?
- A 2002 meta-analysis of 19 placebo-controlled piracetam trials in dementia patients, a 2023 network meta-analysis in frontotemporal dementia, a 2015 review of Lewy body dementia treatments, a rare 1990 trial in healthy volunteers using a drug-induced memory-impairment model, and a 1992 oxiracetam trial.
- How strong is the evidence?
- Thin for healthy users: piracetam shows a favorable effect pooled across dementia trials but worsened symptoms in frontotemporal dementia and showed no benefit in Lewy body dementia, and controlled trials in healthy, non-impaired adults are rare and inconsistent.
- What don't we know yet?
- Whether racetams do anything measurable in healthy adults at commonly used doses, why piracetam's effect direction differs by clinical population, whether modern racetams like phenylpiracetam have any dedicated human trial evidence, and long-term safety with sustained daily use.
- Where can I read the original research?
- Sources at the bottom of this page: Waegemans T, Wilsher CR, Danniau A, et al., Dementia and Geriatric Cognitive Disorders, 2002; and Schifano F, Catalani V, Sharif S, et al., Drugs, 2022.
The short answer: Racetams have real clinical trials behind them — just not the trials the "nootropic" marketing implies. A 2002 meta-analysis pooling 19 placebo-controlled trials found piracetam produced a favorable global clinical impression of change in people with dementia or cognitive impairment. But a 2023 network meta-analysis in frontotemporal dementia found piracetam significantly worsened neuropsychiatric symptoms, and a 2015 review of Lewy body dementia treatments concluded it doesn't appear effective there either. In healthy volunteers specifically — the population most of today's nootropic users belong to — the evidence thins out sharply: one small 1990 trial found aniracetam, not piracetam, reversed drug-induced cognitive impairment in a controlled test. A 2022 pharmacology review of "smart drugs" concluded that any benefit in healthy, non-impaired people remains uncertain and, when reported, tends to be temporary. Most of the underlying trial base was built decades ago, in older or clinically impaired populations — not in the healthy adults now buying these compounds for cognitive enhancement.
What the research shows
The original evidence base: dementia patients, not healthy users
Piracetam, the first racetam, was developed in the 1960s by chemist Corneliu Giurgea, who coined the term "nootropic" to describe drugs meant to enhance learning and memory. A 2002 meta-analysis in Dementia and Geriatric Cognitive Disorders, following Cochrane Collaboration methodology, pooled 19 double-blind, placebo-controlled trials of piracetam in older adults with dementia or cognitive impairment. Using clinical global impression of change as the common outcome, the analysis found a statistically significant difference favoring piracetam over placebo, expressed as both a significant odds ratio and a favorable number needed to treat. That's a genuinely positive result — but it comes from a population of diagnosed patients, using a fairly coarse clinician-rated outcome measure, in trials run mostly before the 2000s.
Where the same drug performs worse, not better
Piracetam's record isn't uniformly positive even within clinical populations. A 2023 network meta-analysis in the American Journal of Geriatric Psychiatry examined pharmacotherapies for neuropsychiatric symptoms in frontotemporal dementia (FTD), pooling seven randomized controlled trials and 243 total participants. High-dose oxytocin showed the largest improvement in neuropsychiatric symptoms. Piracetam went the other direction: it was associated with a significant worsening of neuropsychiatric symptoms (standardized mean difference 3.48, 95% CI 1.58-5.37, p<0.001) and increased caregiver stress (SMD 2.40, p=0.003) relative to placebo. Separately, a 2015 systematic review and meta-analysis in the American Journal of Psychiatry, covering 44 studies across 22 different pharmacological strategies for Lewy body dementia, listed piracetam among the drugs — alongside amantadine, selegiline, and several antipsychotics — that "do not appear to be effective." An earlier, smaller Chinese trial comparing piracetam against combined herbal medicine and rehabilitation therapy in 134 vascular dementia patients found no significant improvement in the piracetam group before versus after 12 weeks of treatment, even as several comparison groups improved.
The rare trial actually run in healthy people
Because most racetam research targeted impaired populations, controlled trials in healthy adults are unusual. One of the few is a 1990 study in the Journal of Psychopharmacology that used a pharmacological impairment model: 26 healthy volunteers received scopolamine, a drug that reliably produces measurable memory and information-processing deficits, on seven separate occasions, then received different nootropic treatments to see which could reverse the impairment. Aniracetam at 1500mg significantly antagonized the scopolamine-induced deficits on both memory and information-processing measures. Piracetam, tested at 2400mg in the same protocol, produced effects that were, in the study's own words, "equal to, or... slightly above, the number which may have occurred by chance" — a result the authors themselves flagged as questionable. This single trial is one of the more direct pieces of human evidence distinguishing between two racetams in an actual healthy population, and it does not treat them as interchangeable.
Other racetams: smaller, older, narrower trials
Oxiracetam has its own, separate trial record, again concentrated in dementia populations. A 1992 double-blind, placebo-controlled trial in Acta Neurologica followed 96 outpatients with cognitive deficiency secondary to primary degenerative dementia for 26 weeks on 1600mg/day of oxiracetam. The treated group showed statistically significant improvement in both standardized cognitive test scores and simple reaction time, while the placebo group showed no significant change; the drug was reported as well tolerated throughout. As with piracetam's positive trials, this evidence comes from a clinically impaired, older population using a specific validated dose and duration — not from healthy adults using the compound off-label for enhancement.
What current pharmacology reviews conclude
Two recent reviews attempt to summarize where this leaves the broader "nootropics" category as actually used today. A 2022 review in Drugs surveyed the prevalence, benefits, and harms of smart drugs — including piracetam alongside stimulants, modafinil, and cholinesterase inhibitors — in healthy students and workers. Its conclusion: while efficacy in people with genuine memory or learning deficits is reasonably well documented, "their effect on non-impaired brains is still to be fully assessed," users generally perceive them as effective with enthusiastic anecdotal reports, but objective improvement, when it appears at all, is typically temporary. A 2022 review in Nutrients cataloguing nootropic types, dosages, and side effects reaches a similar posture: useful clinical background exists for several compounds in impaired populations, alongside far thinner data for healthy users, and specific recommendations differ substantially between the two groups.
What we don't know yet
Whether racetams do anything measurable in healthy, non-impaired adults at the doses commonly used today. The 1990 scopolamine-model trial is one of very few controlled human tests in a healthy population, and it tested only two racetams at single doses under artificial impairment conditions — not everyday cognitive performance.
Why piracetam's effect direction differs by clinical population. It shows a favorable global impression of change pooled across dementia trials, no significant benefit in a Chinese vascular dementia trial, apparent ineffectiveness in Lewy body dementia, and significant worsening of neuropsychiatric symptoms in frontotemporal dementia — with no retrieved study explaining what distinguishes these populations mechanistically.
Whether modern racetams (phenylpiracetam, pramiracetam, and others sold online) have any dedicated human trial evidence at all. Targeted searches for phenylpiracetam, pramiracetam, and oxiracetam trials in healthy adults returned essentially nothing recent; most available data on the racetam family comes from piracetam, aniracetam, and oxiracetam trials run in the 1980s-1990s.
Long-term safety and effect durability with sustained daily use. The dementia trials that exist ran for weeks to months in older, medically monitored populations; there is no equivalent long-duration safety or efficacy data for years of continuous, self-directed use in healthy adults.
Whether reported subjective benefits reflect a real cognitive effect or expectation. The 2022 Drugs review explicitly notes users perceive these compounds as effective with enthusiastic anecdotal reports even where objective evidence is thin — and no trial reviewed here included a rigorous blinded comparison designed to separate a true cognitive effect from expectation in healthy users specifically.
Sources
- Waegemans T, Wilsher CR, Danniau A, Ferris SH, Kurz A, Winblad B. Clinical efficacy of piracetam in cognitive impairment: a meta-analysis. Dementia and Geriatric Cognitive Disorders, 2002;13(4):217-224. DOI
- Schifano F, Catalani V, Sharif S, Napoletano F, Corkery JM, Arillotta D, Fergus S, Vento A, Guirguis A. Benefits and Harms of 'Smart Drugs' (Nootropics) in Healthy Individuals. Drugs, 2022;82(6):633-647. DOI
- Huang MH, Zeng BS, Tseng PT, Hsu CW, Wu YC, Tu YK, Stubbs B, Carvalho AF, Liang CS, Chen TY. Treatment Efficacy of Pharmacotherapies for Frontotemporal Dementia: A Network Meta-Analysis of Randomized Controlled Trials. American Journal of Geriatric Psychiatry, 2023;31(12):1062-1073. DOI
- Stinton C, McKeith I, Taylor JP, et al. Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis. American Journal of Psychiatry, 2015;172(8):731-742. DOI
- Wesnes K, Anand R, Simpson P, Christmas L. The use of a scopolamine model to study the potential nootropic effects of aniracetam and piracetam in healthy volunteers. Journal of Psychopharmacology, 1990;4(4):219-232. DOI
- Rozzini R, Zanetti O, Bianchetti A. Effectiveness of oxiracetam therapy in the treatment of cognitive deficiencies secondary to primary degenerative dementia. Acta Neurologica (Napoli), 1992;14(2):117-126. PubMed
Article records maintained via PubMed. Peptide Proof reports what studies found. It does not provide medical advice, dosing guidance, or treatment recommendations.
Topic: Brain & Cognitive Health
Sources
- Clinical efficacy of piracetam in cognitive impairment: a meta-analysis
- Dementia and Geriatric Cognitive Disorders, 2002 · n=19 · DOI
- Benefits and Harms of 'Smart Drugs' (Nootropics) in Healthy Individuals
- Drugs, 2022 · DOI
- Treatment Efficacy of Pharmacotherapies for Frontotemporal Dementia: A Network Meta-Analysis of Randomized Controlled Trials
- American Journal of Geriatric Psychiatry, 2023 · n=243 · DOI
- Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis
- American Journal of Psychiatry, 2015 · DOI
- The use of a scopolamine model to study the potential nootropic effects of aniracetam and piracetam in healthy volunteers
- Journal of Psychopharmacology, 1990 · n=26 · DOI
- Effectiveness of oxiracetam therapy in the treatment of cognitive deficiencies secondary to primary degenerative dementia
- Acta Neurologica (Napoli), 1992 · n=96
Get the evidence, not the hype.
New research briefs, plainly written and fully sourced. No dosing advice, ever.